Monoclonal antibodies, synthetic and biotechnological derivatives thereof (ScFv or others) are able to recognize the NGF high affinity receptor, TrkA, and act as NGF-antagonist molecules. Pharmacological compositions for therapy, gene therapy, diagnostics of neurological pathologies are also described. Transgenic animal models to study such pathologies are also described.